I
INDIVIOR PLC ORDINARY SHARES
NASDAQ: INDV (Indivior PLC)
Last update: yesterday, 7:32PM12.49
-0.01 (-0.08%)
| Previous Close | 12.50 |
| Open | 12.37 |
| Volume | 878,993 |
| Avg. Volume (3M) | 1,284,545 |
| Market Cap | 1,569,780,608 |
| Price / Sales | 1.44 |
| Price / Book | 145.25 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -0.25% |
| Operating Margin (TTM) | 30.62% |
| Diluted EPS (TTM) | -0.030 |
| Quarterly Revenue Growth (YOY) | 13.30% |
| Current Ratio (MRQ) | 0.830 |
| Operating Cash Flow (TTM) | -240.00 M |
| Levered Free Cash Flow (TTM) | -70.88 M |
| Return on Assets (TTM) | 11.27% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bearish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Indivior PLC | Bearish | - |
AIStockmoo Score
1.5
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 3.75% |
| % Held by Institutions | 89.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Liontrust Investment Partners Llp | 30 Sep 2024 | 1,369,274 |
| Scopia Capital Management Lp | 30 Sep 2024 | 1,284,086 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (Piper Sandler, 28.10%) | Buy |
| 16.00 (Craig-Hallum, 28.10%) | Buy | |
| Median | 16.00 (28.10%) | |
| Average | 16.00 (28.10%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 25 Oct 2024 | 16.00 (28.10%) | Buy | 9.00 |
| 11 Oct 2024 | 15.00 (20.10%) | Buy | 7.46 | |
| Craig-Hallum | 11 Oct 2024 | 16.00 (28.10%) | Buy | 7.46 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |